Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
📍 Aftermath
Q32 Bio's stock surged after announcing positive 36-week topline results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in alopecia areata, with 40% of patients achieving a key hair regrowth mark. The company's stock jumped 60-83% following the release of the mid-stage trial results, which showed meaningful hair regrowth and safety in severe alopecia areata at 36 weeks. The story quieted without further updates in the provided headlines.
Epilogue added 43d ago, after coverage quieted.
Sources (10)
- Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark Stock Titan · 46d ago
- Q32 Bio stock surges 83% on positive alopecia drug trial data qz.com · 46d ago
- Q32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB) Yahoo Finance · 46d ago
- Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PR Newswire · 46d ago
- Why Q32 Bio Stock Skyrocketed Today The Motley Fool · 46d ago
- QTTB Stock Rockets On Volatility And Cash-Rich Balance Sheet StocksToTrade · 46d ago
- QTTB: Bempikibart achieved meaningful hair regrowth and safety in severe alopecia areata at 36 weeks TradingView · 46d ago
- QTTB Maintained by Oppenheimer -- Price Target Raised to $40 GuruFocus · 46d ago
- Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Yahoo Finance · 46d ago
- Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors Fierce Biotech · 46d ago broke it first
The brief
Q32 Bio reported topline results from Part B of the SIGNAL-AA clinical trial for Bempikibart. The 36-week data indicates that 40% of patients achieved a key hair regrowth mark, with the treatment positioned as a potential rival to current JAK inhibitors.
Coverage from outlets including Fierce Biotech, Yahoo Finance, and Qz.com highlights a substantial increase in Q32 Bio stock value, with reports varying between 60% and 83%. Oppenheimer has reportedly raised the company's price target to $40, citing the trial results and a cash-rich balance sheet as factors in recent market activity.
Observers are looking toward future phases of the SIGNAL-AA trial. Coverage does not yet specify the timeline for subsequent trial stages or potential regulatory submission dates.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.
Quick answers
What is the primary driver of Q32 Bio's recent stock movement?
Market activity follows the announcement of positive 36-week topline results from Part B of the SIGNAL-AA clinical trial for the drug Bempikibart.
How effective was Bempikibart in the reported trial?
According to trial data, 40% of patients achieved a key hair regrowth mark at the 36-week interval.
What is the analyst outlook on Q32 Bio?
Oppenheimer has maintained its position on the company and raised the price target to $40.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Micron Stock Is Falling Even Harder Today and It’s an Ominous Sign
Micron Technology shares are experiencing a sharp decline as a broader semiconductor sell-off intensifies, fueling debate over the company's valuation.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Why another shocking Meta capex number may keep the stock underwater
Meta stock has fallen for seven consecutive days as investors weigh concerns over high capital expenditures ahead of the upcoming Q2 earnings report.
Wall St climbs after US, Iran pause conflict; focus on Fed, earnings
U.S. stocks surge as a pause in U.S.-Iran tensions lifts markets, but a Fed decision this week keeps traders on edge.
Palantir: Rule Of 145% May Fail (Rating Downgrade)
Palantir faces conflicting market signals as a potential rating downgrade clashes with bullish growth estimates and rally predictions.